By admin | Published:
November 6, 2007
November 6, 2007
Philip Barter
Gordon Tomaselli
REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
N Engl J Med 2007;357
PHILIP BARTER, Heart Research Institute, Sydney, Australia
COMMENT: GORDON TOMASELLI, Johns Hopkins University, Baltimore
A randomized double-blind study involving over 15,000 patients at high cardiovascular risk which looked at the new agent torcetrapib (an inhibitor of cholesteryl ester transfer protein, CETP) resulted in higher mortality in the experimental arm. The study compared torcetrapib plus atorvastatin with atorvatstin alone. Inhibition of CETP increases HDL levels and reduces LDL levels and should combat atherosclerosis. Sarah Maxwell spoke with Philip Barter who presented data on the ILLUMINATE trial at the American Heart Association meeting in Orlando.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
November 6, 2007
November 6, 2007
Uwe Zeymer
REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
UWE ZEYMER, Herzzentrum Ludwigshafen, Germany
The glycoprotein 2B 3A antagonist eptifibatide has performed as well as standard abciximab therapy in patients receiving primary angioplasty for acute myocardial infarction. So according to Uwe Zeymer who presented findings on this it can be used in this setting just as it is already being used in elective PCI. Sarah Maxwell interviewed Dr Zeymer at the Orlando conference.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
November 5, 2007
November 5, 2007
Anthony Fung
REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
ANTHONY FUNG, University of British Columbia, Vancouver
Brief courses of antiplatelet therapy with the glycoprotein 2b 3a inhibitor are just as effective as longer infusions for patients receiving non-emergency percutaneous intervention. So said Anthony Fung at the first session of Late breaking Clinical Trials held at the American Heart Association’s annual meeting in Orlando. He talked with Peter Goodwin about his findings.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
November 5, 2007
November 5, 2007
Laura Mauri
Raymond Gibbons
REFERENCE: Late Breaking Special Session, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
LAURA MAURI, Brigham and Woman’s Hospital, Boston Massachusetts
COMMENT: RAYMOND GIBBONS, Mayo Clinic, Rochester, Minnesota
The largest study to date looking at long-term outcomes of bare metal stents as compared with drug eluting stents in patients who have undergone PCI was presented to the American Heart Association annual meeting. There was no increased mortality for patients who received drug eluting stents in a Massachussets based population. Sarah Maxwell spoke with investigator to Laura Mauri at the Orlando meeting.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Posted in Cardiovascular | Tagged cardiovascular, comments, drug, drugs, heart, investigation, journal, patient, podcast, podcasting, presented, stent, stenting, stents, study |
By admin | Published:
September 5, 2007
September 5, 2007
Gabriel Steg
Freek Verheugt
REFERENCE: Hotline III, number 709, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria
GABRIEL STEG, Hôpital Bichat, Paris
COMMENT: FREEK VERHEUGT, Radboud University Nijmegen Medical Centre, Nijmegen
The GRACE registry looking at over 60 000 patients with ST elevation myocardial infarction has shown that patients live longer if they receive bare metal stents than if they get drug eluting stents. Gabriel Steg presented these latest data at the ESC meeting in Vienna. Sarah Maxwell discussed the findings with him.
Freek Verheugt comments on the interview with Gabriel Steg.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
September 5, 2007
September 5, 2007
Stefano Ghio
Cecilia Linde
REFERENCE: Hotline III, 3222 page 315, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria
STEFANO GHIO, San Matteo University Hospital, Italy
COMMENT: CECILIA LINDE, Karolinska University Hospital, Stockholm
The standard echocardiographic criteria for selecting patients to receive cardiac resynchronisation are not adequate according to Stefano Ghio. During the ESC Congress in Vienna he presented results from the PROSPECT trial and afterwards he talked with Sarah Maxwell. Cecilia Linde gave Nicola Solomon her comments on the findings.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
September 5, 2007
September 5, 2007
Raul Moreno
REFERENCE: Abstract 3103, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria
RAUL MORENO, University Hospital La Paz, Madrid
Results from a large meta analysis suggest that drug eluting stents have a greater benefit when the risk of restenosis increases. This could affect the “off label” use of these stents. Raul Moreno, of the University Hospital La Paz, Madrid, discussed his findings with Derek Thorne.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
September 5, 2007
September 5, 2007
Nicolas Amabile
REFERENCE: Abstract 1967, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria
NICOLAS AMABILE, University of Marseille School of Medicine
A French study presented at the ESC congress may have found a link between periodontitis and coronary artery disease: although further study is needed. Nicolas Amabile, of the University of Marseille School of Medicine, discussed his data with Derek Thorne.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
By admin | Published:
September 5, 2007
September 5, 2007
Eva Swahn
REFERENCE: HOTLINE II, Monday 8am, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria
EVA SWAHN, University Hospital Linköping, Sweden
COMMENT: ECKART FLECK, Deutsches Herzzentrum, Berlin
Women who undergo selective invasive treatment for non-ST elevation acute coronary syndromes do better than those who receive routine early invasive treatment. This is according to the OASIS 5 study from Sweden that randomised women to either of the two approaches. The findings suggest that females with non-ST elevation ACS should be approached differently from their male counterparts. Sarah Maxwell interviewed OASIS investigator Eva Swahn at the ESC meeting in Vienna. Eckart Fleck of the Deutsches Herzzentrum in Berlin gave his comments on her comments to Derek Thorne.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Rosuvastatin: No Significant Benefit for Older Patients with Systolic Heart Failure: CORONA Study Results
November 6, 2007
Ake Hjalmarson
Gordon Tomaselli
N Engl J Med 2007;357
AKE HJALMARSON, Sahlgrenska University, Göteborg
COMMENT: GORDON TOMASELLI, Johns Hopkins University, Baltimore
The lipid lowering agent rosuvastatin did not bring a significant benefit to older patients with systolic heart failure, according to the findings of the CORONA study released at the American Heart Association sessions in Orlando. Ake Hjalmarson talked with Peter Goodwin about the implications this has for using statins in older patients with heart failure.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.